Source: Annual Congress 2010 - Pulmonary hypertension updates
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Savale, R. Magnier, J. Le Pavec, X. Jaïs, D. O‘Callaghan, D. Montani, D. Natali, M. Humbert, G. Simonneau, O. Sitbon (Clamart, Caen, France). Efficacy and safety of bosentan in portopulmonary hypertension according to the severity of liver disease. Eur Respir J 2010; 36: Suppl. 54, 1914

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of tadalafil in portopulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Experience with inhaled iloprost and bosentan in portopulmonary hypertension Source: Eur Respir J 2007; 30: 1096-1102 Year: 2007 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Iloprost treatment in portopulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment Source: Eur Respir J 2014; 43: 1516-1519 Year: 2014 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Source: Eur Respir J 2003; 21: 912 Year: 2003 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006 Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Sildenafil for patients with portopulmonary hypertension, candidates to hepatic transplant Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013